Ligands organométalliques

PD 168393 is a potent and selective irreversible inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. It is synthesized through advanced chemical processes, designed to specifically target and covalently modify the ATP-binding site of EGFR. The mode of action involves the irreversible binding to the cysteine residue in the ATP-binding pocket, leading to the inhibition of EGFR autophosphorylation and subsequent downstream signaling pathways.

Inhibits interaction between small GTPase Rab27a and its effector JFC1 (synaptotagmin-like protein1, Slp1). These proteins regulate neutrophil exocytosis, decrease neutrophil infiltration in liver and kidneys and reduce extracellular ROS production by NAPDH oxidase. Thus, nexinhibib20 suppresses systemic inflammation.

MT 63-78 is a synthetic peptide, which is a product of advanced bioengineering technologies with the potential to modulate specific physiological pathways. It is derived from rational design processes that utilize the sequencing of amino acids to achieve a precise formulation that can interact with biological targets at a molecular level. Its mode of action involves binding to specific receptors or proteins, thereby influencing signaling pathways that are critical in cellular processes.

Inhibits MET, VEGFR1-3, Tie and Ron tyrosine kinases; antineoplastic

Interleukin-13 human is a recombinant cytokine, which is derived from the expression of the human IL-13 gene in suitable host systems, such as E. coli or mammalian cells. This cytokine belongs to the interleukin family and plays a pivotal role in the immune response by modulating inflammatory pathways. The mode of action of interleukin-13 involves binding to specific cell surface receptors, IL-13Rα1 and IL-13Rα2, which facilitates the activation of various intracellular signaling cascades, including the JAK/STAT pathway. This promotes the differentiation and proliferation of certain immune cells, influencing the production of IgE and contributing to the regulation of inflammatory responses.

Sunitinib is a tyrosine kinase inhibitor drug. It is a drug that is used as a treatment for renal cell carcinoma, gastrointestinal stromal tumor, and other solid tumors. This drug inhibits tyrosine kinases such as VEGFRs, this prevents tumour growth and pathologic angiogenesis.

SC144 hydrochloride is a small molecule inhibitor, which is synthetically derived and developed to target specific signaling pathways in cancer cells. This compound acts as an inhibitor of gp130, a co-receptor involved in the interleukin-6 (IL-6) family cytokine signaling. It effectively disrupts the downstream activation of the JAK/STAT3 pathway, which is often upregulated in various cancer types, contributing to tumor growth and survival.

Muscle relaxant; anti-inflammatory

Efficient chemiluminescent NH2-coupling reagent for detection of proteins

Ligand of plasminogen; used for bleeding control

Apatinib, also known as rivoceranib, is an inhibitor of the vascular endothelial growth factor receptor 2 (VEGFR2) tyrosine kinase. Apatinib targets VEGFR2 with its action and has proven to have strong anti-tumor effects in human cancers. In studies in mice, apatinib acted as an Inhibitor of VEGFR2 and played an antiangiogenic effect. Apatinib has been suggested for the treatment of ischemia-induced proliferative retinopathy and neovascular age-related macular degeneration.

Microcolin B is a lipopeptide, which is a type of secondary metabolite. It is derived from marine cyanobacteria, specifically from the genus Lyngbya. This compound exhibits a complex mode of action, primarily by inhibiting the activity of protein kinase C (PKC), an enzyme that plays a crucial role in regulating immune responses and cell proliferation.

Inhibits human and mouse diacylglycerol O-acyltransferase 1 (DGAT-1) with IC50 values of 9 and 22 nM, respectively. Selective for DGAT-1 over DGAT-2 (IC50 = 53 µM), acyl coenzyme A transferase (IC50 = 296 µM) and other acyltransferases. Reduces plasma and liver triglycerides, FFA, chylomicron secretion and increases HDL cholesterol in vivo.

Multi-kinase inhibitor; inhibits epoxide hydrolase; antineoplastic

Recombinant protein against VEGF(A); binds placental growth factor (PIGF)

Uricosuric agent

Sodium channel blocker; anti-arrhythmic agent

Inhibits acetylcholinesterase (AChE); antispasmodic agent

Inhibitor of acetylcholinesterase

C16(Plasm) LPC is a lysophosphatidylcholine, a type of lysophospholipid derived predominantly from plasma membrane phospholipids. It originates from the enzymatic action of phospholipase A2, which cleaves the fatty acid chain, typically at the sn-2 position. This leaves behind the lysophospholipid with a single acyl chain.